

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 904 110 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**24.07.2002 Bulletin 2002/30**

(51) Int Cl.7: **A61K 45/06, A61P 43/00**

(21) Application number: **97906115.7**

(86) International application number:  
**PCT/EP97/00873**

(22) Date of filing: **24.02.1997**

(87) International publication number:  
**WO 97/31654 (04.09.1997 Gazette 1997/38)**

### (54) NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM DRUGS

STICKSTOFFOXYDABGEBENDES PRÄPARAT ZUR REDUZIERUNG DER TOXIZITÄT VON  
WIRKSTOFFEN

DONNEURS D'OXYDE NITRIQUE CAPABLES DE DIMINUER LA TOXICITE DE MEDICAMENTS

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT  
SE**

Designated Extension States:  
**LT SI**

(30) Priority: **26.02.1996 IT MI960352**

(43) Date of publication of application:  
**31.03.1999 Bulletin 1999/13**

(60) Divisional application:  
**02008079.2 / 1 221 326**

(73) Proprietor: **NICOX S.A.  
75116 Paris (FR)**

(72) Inventor: **DEL SOLDATO, Piero  
I-20052 Monza (IT)**

(74) Representative: **Sama, Daniele, Dr.  
Sama Patents  
Via Morgagni, 2  
20129 Milano (IT)**

(56) References cited:  
**WO-A-96/00073**

- **J GASTROENTEROL HEPATOL, 1994, 9 SUPPL 1 PS40-4, AUSTRALIA, XP000675240 WALLACE JL ET AL: "Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity."**

EP 0 904 110 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

[0001] The present invention relates to the prevention or the reduction of the iatrogenic toxicity. More particularly it relates to the reduction of toxicity caused by drugs at renal and/or gastrointestinal and/or respiratory level.

5 [0002] It is well known that the toxicity from drugs is assuming a more and more important role in human pathology. It suffices to consider the gastropathy caused by anti-inflammatory drugs which implies an yearly cost in the range of some billions of dollars for the U.S. public administration. See for instance Bloom, B.S. Am. J. Medicine 84 (supplement 2A), 20, 1988, which reports the yearly costs for the arthritis treatment in USA amounting to more than 12 billions of dollars, of which more than 30% is attributable to the care of the side effects connected to the anti-inflammatory/10 antiarthritic pharmacological treatment.

10 [0003] Likewise the nephropathy caused by antibiotics can mean for the single patient losses of thousands of dollars to cover hospitalization expenses. See for instance Berndt W.O. et al. in "Principles of Pharmacology" Munson P.L. Ed. p. 685, 1995.


15 [0004] An object of the present invention consists in the use of compounds capable of reducing the toxicity caused by non nitroderivative drugs to the gastrointestinal and/or renal and/or respiratory apparatus.

20 [0005] It has been surprisingly and unexpectedly found that this is possible if organic compounds containing the -ONO<sub>2</sub> function, or inorganic compounds containing the -NO group are employed, said compounds being characterized in that they are nitric oxide NO donors, i.e. when they are put into contact in vitro with cells of the basal endothelium, platelets, etc., and after incubation of 5 minutes at the temperature of 37°C are capable of releasing NO and activating the cGMP (Guanosine cyclic 3',5'-(hydrogen phosphate)) synthesis, as determined by the specific tests utilized, which will be described in detail in the examples.


25 [0006] The unexpected and surprising results of the claimed invention are also shown by the following fact: the combination of the nitroderivatives of the invention with a non nitroderivative drug is useful not only to reduce the toxicity of the drug but also to eliminate the disadvantages related to the nitroderivatives administration.

30 For example nitroglycerin, when given with enalapril to rats, following repeated subcutaneous administration at the dose of 1 mg/kg per day, did not cause any tolerance, differently from nitroglycerin alone. Therefore the combination of the present invention results in the so called lower tolerance by chronological administration pharmaceutical compositions. This is a great advantage since no problem arises also by taking nitroderivatives for a long time and maintaining the same effectiveness of the nitroderivative compounds.


35 [0007] The organic compounds containing -ONO<sub>2</sub> functions which can be mentioned as an example, are the following, which are reported in The Merck Index 11th Ed. - 1989 and prepared with the known methods, for instance those reported in the Merck, incorporated herein by reference.: clonitrate (3-chloro-1,2-propanediol dinitrate) (Merck No. 2390) having the formula C<sub>3</sub>H<sub>5</sub>ClN<sub>2</sub>O<sub>6</sub> and formula of structure




45 erythrityltetranitrate (1,2,3,4 butanetetroltetranitrate) (Merck No. 3622) having the formula C<sub>4</sub>H<sub>6</sub>N<sub>4</sub>O<sub>12</sub> and formula of structure




55 mannitol hexanitrate (Merck No. 5630) having the formula C<sub>6</sub>H<sub>8</sub>N<sub>6</sub>O<sub>18</sub> and formula of structure




15 nicorandil (N-[2-(nitrooxy)ethyl]-3-pyridine-carboxamide) (Merck No. 6431) having the formula  $\text{C}_8\text{H}_9\text{N}_3\text{O}_4$  and formula of structure




nitroglycerin (1,2,3 propanetriol trinitrate) (Merck No. 6528) having the formula  $\text{C}_3\text{H}_5\text{N}_3\text{O}_9$  and formula of structure



pentaerythritoltetranitrate (2,2-bis [(nitrooxy)-methyl]-1,3-propanedioldinitrate) (Merck No. 7066) having the formula  $\text{C}_5\text{H}_8\text{N}_4\text{O}_{12}$  and formula of structure




pentrinitrol (2,2-bis[(nitrooxy)methyl] -1,3-propanediolmononitrate) (Merck No. 7094) having the formula  $\text{C}_5\text{H}_9\text{N}_3\text{O}_{10}$  and formula of structure



propatylnitrate (2-ethyl-2-[(nitrooxy)methyl]-1,3-propanedioldinitrate) (Merck No. 7821) having the formula  $\text{C}_6\text{H}_{11}\text{N}_3\text{O}_9$


and formula of structure



10

trotnitratephosphate (2,2',2"-nitrylrisethanoltrinitrate phosphate) (salt 1:2) (Merck No. 9682) having the formula  $\text{C}_6\text{H}_{18}\text{N}_4\text{O}_{17}\text{P}_2$  and formula of structure

15



20

[0008] Among the inorganic compounds containing the -NO group, nitroprussiates can be mentioned, such as for instance:

25 sodiumnitroprussiate (pentakis (cyano-C)nitrosylferrate (2-)disodium) (Merck No. 8600) having the formula  $\text{Na}_2[\text{Fe}(\text{CN})_5\text{NO}]$ .

[0009] Other compounds containing the - $\text{ONO}_2$  function are reported in patent applications in the name both of the Applicant WO 95/30641; WO 95/09831; WO 94/12463 and of others WO 94/04484. These patent applications PCT/WO are herein incorporated by reference both for the compounds and for the preparation processes.

[0010] The nitric oxide NO donors compounds of the invention are indicated hereinafter by the term DON-NO.

30 [0011] Among the drugs not containing nitroderivative groups causing renal and/or gastrointestinal and/or respiratory toxicity, the following compounds belonging to different therapeutic classes, can be mentioned, as an example:

anti-tumoral drugs among which cisplatin, 5 fluoro-uracil can be mentioned;

immunodepressive drugs among which cyclosporin can be cited;

35 anti-viral drugs among which acyclovir can be cited;

non-steroidal anti-inflammatory drugs, among which ibuprofen, indomethacin, diclofenac, ketorolac, naproxen, ketoprofen, mefenamic acid, flunixin, flufenamic acid, niflumic acid can be mentioned;

anti-thrombotic drugs among which aspirin can be mentioned;

steroidal anti-inflammatory drugs among which cortisone, dexamethasone, methylprednisolone can be mentioned;

40 antibiotics among which ciprofloxacin, gentamicine can be mentioned;

inhibitors of the angiotensin-converting enzyme (ACE) among which captopril, enalapril can be mentioned;

beta-adrenergic antagonists, e.g. atenolol, metoprolol, timolol, propanol, etc. Also for these agents respiratory toxicity was reduced by the administration of the nitroderivatives of the invention.

45 [0012] All these drugs are reported in the Merck Index (see above) herein incorporated by reference.

[0013] The preferred compounds as drugs not containing the nitroderivative group of which it is desired to prevent or reduce the toxicity, are antitumoral drugs, in particular cis-platinum (cisplatin); immunodepressive drugs, in particular cyclosporin; steroidal anti-inflammatory drugs, in particular dexamethasone, methylprednisolone; inhibitors of the angio-tensin-converting enzyme (ACE), in particular enalapril, captopril.

50 [0014] The administration of the compounds of the present invention can be carried out by oral, parenteral or transdermic way and they are generally administered simultaneously, successively or previously to the drug not containing the nitroderivative group which causes the gastrointestinal and/or renal and/or respiratory toxicity. The transdermic way is the preferred one and the compounds of the invention are administered under the form of patches or plasters. In particular conventional patches based on nitroglycerine are preferred, according to an embodiment of the present invention.

The dosages are the conventional ones already utilized for the DON-NO for the cardiovascular indications in human therapy. A commercial patch is generally utilized for one day or two days and then replaced. Slow release-patches could be used for more days before being replaced. Sometimes also two patches a day, each for twelve hours, can

be utilized. This procedure is generally preferred when a greater effectiveness is required.

[0015] Such dosages are preferred since they do not cause significant side effects as those typical of this class of drugs, for instance cephalea, marked hypertension, etc.

[0016] The dosage ranges for the human therapy generally vary between 5-15 mg/24 h in 1-2 applications.

5 [0017] The compounds of the invention containing the  $-ONO_2$  functions or the  $-NO$  group producing the effects of the invention, as already said, must meet the test in vitro defined herein in detail.

[0018] In particular the test relates to the generation of nitric oxide from the NO donors of the present invention, among which, for instance, nitroglycerine, nicorandil, nitro-prussiate, etc., when they are put in the presence of endothelial cells (method a), or platelets (method b).

10 a) Endothelial cells

Cells of the human umbilical vein, spread on the plate, with density of  $10^3$  cells/plate were incubated with scalar concentrations of NO donor (1-100  $\mu$ g/ml) for 5 minutes. The incubation medium (physiologic solvent, for instance Tyrode) was then analyzed to determine the capacity to generate NO, by means of:

15 - 1) the determination of nitric oxide by chemiluminescence;  
 2) the cGMP determination (cyclic GMP No. 2715 of the above mentioned Merck).

20 As regards the analysis by chemiluminescence, an amount equal to 100  $\mu$ l was injected in the reaction chamber of a chemiluminescence analyser containing glacial acetic acid and potassium iodide. The nitrites/nitrates present in the medium in these conditions are converted into NO which is then determined after its reaction with ozone, with consequent generation of light. As it usually occurs in the devices measuring chemiluminescence, the produced luminescence is directly proportional to the NO levels generated and can be measured by the suitable photomultiplier unit of a chemiluminescence analyser. The photomultiplier converts the incident light into electric voltage, which is then quantitatively recorded. On the basis of a calibration curve, prepared with scalar concentrations of nitrite, it was possible to determine quantitatively the generated NO concentration. For instance, from the incubation of 100  $\mu$ moles of nicorandil, an amount equal to about 10  $\mu$ moles of NO was generated.

25 As regards the cGMP determination, a portion of the incubation medium (equal to 100  $\mu$ l) was centrifuged at 1000 revolutions for 20 seconds. The supernatant was discharged and the sediment taken again with iced phosphate buffer (pH 7.4). The cGMP levels produced were tested, by specific immuno-enzymatic reactants. From such experiments it resulted that, in these experimental conditions, the incubation with one of the various tested NO donors, caused a significant increase of cGMP with respect to the values obtained in absence of a NO donor. For instance, further to incubation with 100  $\mu$ moles of sodium nitroprussiate, an increase of about 20 times the value obtained with the incubation of only the vehicle without the NO donor was recorded.

30 b) Platelets

35 Washed human platelets, prepared analogously with what described by Radomski et al, (Br. J. Pharmacol. 92, 639-1987), were utilized. Aliquots of 0.4 ml were incubated with scalar concentrations of NO donors (1-100  $\mu$ g/ml) for 5 minutes. The incubation medium (f.i. Tyrode) was then analysed to determine the capacity of generating NO, by determination of nitric oxide by chemiluminescence and cGMP, with the modalities described in the previous paragraph, for the analyses carried out on the endothelial cells. As to the determination by chemiluminescence, also in this case, on the basis of a calibration curve, prepared with scalar concentrations of nitrite, it was possible to determine quantitatively the concentration of generated NO. For instance, after incubation of 100  $\mu$ moles of nicorandil, an amount equal to 35  $\mu$ moles of NO was generated.

40 As regards the cGMP determination, also in these experimental conditions, it resulted that the incubation with one of the various NO donors tested caused a significant increase of cGMP with respect to the values obtained in absence of a NO donor. For instance, after incubation with 100  $\mu$ moles of sodium nitroprussiate, an increase of about 30 times the value obtained with the incubation of only the vehicle without the NO donor, was recorded.

45 [0019] In conclusion, from said tests it results that all the NO donors according to the present invention, after incubation with endothelial cells or platelets for 5 minutes, are capable to generate NO, and to activate the cGMP synthesis in a concentration-dependent way, as determined by the utilized specific tests.

[0020] The following examples are given for illustrative purpose but are not limitative of the present invention.

EXAMPLESEXPERIMENTAL STUDIES ON COMBINATIONS BASED ON POTENTIALLY TOXIC DRUGS AND ON NO DONORS (INDICATED BY DON-NO)

5

A) ANIMALS STUDIES

[0021]

## 10 1) STUDY OF THE RENAL FUNCTIONALITY AFTER ADMINISTRATION OF ANTI-TUMORAL COMPOUNDS (CISPLATIN):

Sprague-Dawley male rats were daily treated with vehicle (physiologic saline solution, 0.9% sodium chloride, intraperitoneal (i.p.)) or cisplatin (i.p.) (5 mg/kg). Some animals received a daily dose of a NO donor, sodium nitroprussiate 0.2-1 mg/kg subcutaneous (s.c.). After five days the animals were sacrificed and the plasmatic urea and the plasmatic concentration of creatinine were determined. The data were analysed according to the bio-statistic methods commonly used.

As shown in Table 1, it resulted that the rats treated with cisplatin only showed meaningfully high levels of plasmatic urea and of creatinine, with respect to the control values (group receiving only the vehicle).

On the contrary, in animals, to which cisplatin and NO donor were administered, the biochemical parameters did not result meaningfully different from the control values.

## 20 2) STUDY OF THE RENAL FUNCTIONALITY AFTER ADMINISTRATION OF IMMUNO-DEPRESSIVE COMPOUNDS (CYCLOSPORIN):

Sprague-Dawley male-rats were daily treated with vehicle (physiologic saline solution, 0.9% sodium chloride, i.p.) or intraperitoneal cyclosporin (5 mg/kg i.p.). Some animals received a daily dose of a NO donor, sodium nitroprussiate 0.2-1 mg/kg s.c. After eighteen days the animals were sacrificed and the plasmatic concentration of creatinine and the activity of N-acetyl-beta D-glycosaminidase (NAG) in the urines were measured. The data were analysed according to the bio-statistic methods commonly used.

As shown in Table 2, it resulted that the rats treated with cyclosporin only showed meaningfully high levels of blood creatinine and of above urine NAG with respect to the control values (group receiving only the vehicle).

On the contrary, in animals, to which cyclosporin and DON-NO donor were administered, the biochemical parameters did not result meaningfully different from the control values.

## 30 3) STUDY OF THE RENAL FUNCTIONALITY AFTER ADMINISTRATION OF ANTI-VIRAL COMPOUNDS (ACYCLOVIR):

Sprague-Dawley male rats were treated with vehicle (physiologic saline solution, 0.9% sodium chloride, i.p. a day) or intraperitoneal acyclovir (150 mg/kg i.p. a day). Some animals received a daily dose of a DON-NO (nitroglycerine 1-10 mg/kg s.c. a day). After fifteen days the animals were sacrificed and the plasmatic concentration of creatinine was determined. The data were analysed according to the conventional bio-statistic methods commonly used.

As shown in Table 1, it resulted that the rats treated with only acyclovir showed meaningfully high levels of blood creatinine with respect to the control values (group receiving only the vehicle).

On the contrary, in animals, to which acyclovir and DON-NO were administered, the biochemical parameters did not result meaningfully different from the control values (group receiving only the vehicle).

## 40 4) STUDY OF THE RENAL FUNCTIONALITY AND OF THE GASTROINTESTINAL TOLERABILITY IN ARTHRITIC RATS AFTER ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS (IBUPROFEN, NAPROXEN, INDOMETHACIN, DICLOFENAC) OR ANTI-THROMBOTICS (ASPIRIN) :

Sprague-Dawley female rats were rendered arthritic, by an intracaudal injection of butyric *Micobacterium* inactivated by heat (0.6 ml suspended in 0.1 ml of mineral oil). After eighteen days, when the arthritic pathology was fully developed, the animals were daily treated with the vehicle (physiologic saline solution, 0.9% sodium chloride, i.p. a day) or NSAID [ibuprofen (60 mg/kg i.p. a day); indomethacin (10 mg/kg/ i.p. a day); diclofenac (12 mg/kg i. p. a day; or naproxen (12 mg/kg i.p. a day)] or aspirin (250 mg/kg i.p. a day). Some animals received a daily dose of a DON-NO (sodium nitroprussiate 0.2-1 mg/kg s.c.; or nitroglycerin 1-10 mg/kg s.c. a day). After five days the animals were sacrificed and the plasmatic concentration of creatinine was determined. The data were analysed according to the conventional bio-statistic methods commonly used.

As shown in Table 3, it resulted that the rats treated with only NSAID or aspirin showed meaningfully high levels of blood creatinine with respect to the control values (group receiving only the vehicle); such animals showed also a marked pathology affecting the gastrointestinal apparatus, having a severity ranging from the mucous erosion to ulcer involving the muscular layer, intestinal adherences, abscesses, peritonitis. In the other groups, treated with the vehicle or combining DON-NO plus NSAID or aspirin, the pathology was either of much smaller entity or

even absent.

Moreover in the animals to which a NSAID or aspirin and a DON-NO were administered, the biochemical parameter did not result significantly different from the control values.

5) STUDY OF THE RENAL FUNCTIONALITY AND OF THE GASTROINTESTINAL TOLERABILITY IN HYPERTENSIVE RATS, AFTER ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS (DICLOFENAC) :

10 Sprague-Dawley male rats, spontaneously hypertensive (with systolic pressure variable between 180-220 mmHg) were daily treated with the vehicle (physiologic saline solution, 0.9 sodium chloride, i.p.) or NSAID[diclofenac (12 mg/kg i.p.)]. Some animals received a daily dose of an organic nitrate (nitroglycerin 1-10 mg/kg s.c. a day). After five days the animals were sacrificed and the plasmatic concentration of creatinine was determined. The data were analysed according to the conventional bio-statistic methods commonly used.

15 As shown in Table 4, it resulted that the rats treated with NSAID only showed meaningfully high levels of blood creatinine with respect to the control values (group receiving only the vehicle); such animals showed at the post-mortem examination also a marked pathology affecting the gastrointestinal apparatus, of severity variable from the mucous erosion to ulcer involving the muscular layer, intestinal adherences, abscesses, peritonitis. In the other groups, treated with the vehicle or combining DON-NO plus NSAID, the pathological picture affecting the gastrointestinal apparatus was either of much smaller entity or even absent.

20 Moreover in the animals to which diclofenac and DON-NO were administered, the biochemical parameter did not result significantly different from the control values.

6) STUDY OF THE GASTROINTESTINAL TOXICITY AFTER ADMINISTRATION OF STEROIDAL ANTI-INFLAMMATORY COMPOUNDS (METHYLPREDNISOLONE):

25 Sprague-Dawley male rats were daily treated with the vehicle (physiologic saline solution, 0.9 sodium chloride, i.p.) or intraperitoneal methylprednisolone (5-10 mg/kg i.p.).

Some animals received a daily dose of a DON-NO (sodium nitroprussiate 0.2-1 mg/kg s.c.). After eighteen days the animals were sacrificed.

30 At the postmortem examination it resulted (Tab. 5) that such rats showed a marked pathology affecting the gastrointestinal apparatus, of severity variable from the mucous erosion to ulcer involving the muscular layer, intestinal adherences, abscesses, peritonitis. In the other groups, treated with the vehicle only or with the combination nitrate plus steroid, the pathology was either of much smaller entity or even absent.

7) STUDY OF THE EFFECTS OF NITROXYBUTYLNAPROXEN (NO-NAPROXEN) ON CAPSAICIN-INDUCED BRONCHOCONSTRICTION IN ENALAPRIL-TREATED GUINEA PIGS

35 Capsaicin-induced bronchoconstriction in guinea pigs is an animal model related to the ability of angiotensin-converting-enzyme inhibitors to provoke cough in patients (Subissi et al, J. Cardiovasc. Pharmacol. 20/1, 139-146, 1992).

NO-naproxen (2-(6-methoxy-2-naphthyl)propionate of 4-hydroxy-butyl) was synthetized according to Ex. 1, formula V of International patent WO 95/09831.

40 Experimental conditions were as previously described by Del Soldato et al (J. Pharmacological Methods 5, 279, 1981). Female guinea pigs weighing 300-400 g were anesthetized through intraperitoneal injection of sodium 5,5 diethylbarbiturate (200 mg/kg) and kept under artificial respiration at constant positive pressure. Jugular right vein was cannulated for the administration of the compounds. Animals received intraduodenally enalapril (10 mg/kg), vehicle (carboxymethyl cellulose 2% by weight) and/or NO-naproxen (10 mg/kg). Forty-five minutes later, it was injected intravenously 0.1 ml capsaicin (1 µg/kg). Before and after capsaicin injection, tidal air changes were measured by means of modified Konzett apparatus connected to a polygraph amplifier.

45 Results were calculated as ratio of the responses obtained before and after the administration of each treatment, expressed as % of the vehicle (control) response and shown in Table 7.

As shown in Table 7, NO-naproxen was able to reduce capsaicin-induced bronchoconstriction in enalapril treated guinea pigs. Enalapril increased capsaicin-induced bronchoconstrictive response, when administered alone.

50 B) STUDY ON PATIENTS

STUDY OF THE RENAL FUNCTIONALITY IN PATIENTS AFTER ADMINISTRATION OF ANTI-TUMORAL DRUGS (CISPLATIN).

55 [0022] In some patients, separately observed, and in uncontrolled studies was evaluated the acute effect of some drugs such as cisplatin, alone or in the presence of a nitroglycerin patch.

[0023] The mono-administration of intraperitoneal cisplatin (90 mg per m<sup>2</sup>) to patients, which needed an antitumoral therapy, caused a significant increase of blood creatinine in the first 24 hours, with respect to the initial values.

[0024] As it results from Table 6, when the patients were submitted to daily co-treatment with the nitroglycerin patch approximately releasing 15 mg/24 hours of nitroglycerin when the patch came into contact with the skin, such increase was much more limited and however significantly not different from the initial values.

[0025] The data were analysed according to the conventional biostatistic methods commonly used.

5

TABLE 1

STUDY OF THE RENAL FUNCTIONALITY IN RATS, AFTER THE REPEATED TREATMENT WITH CISPLATIN OR ACYCLOVIR, IN THE PRESENCE OR NOT OF NO DONOR. THE DATA ARE EXPRESSED AS PERCENT VARIATION WITH RESPECT TO THE CONTROL VALUE (GROUP TREATED WITH ONLY THE VEHICLE).		
TREATMENT	BLOOD UREA	BLOOD CREATININE
VEHICLE	100	100
CISPLATIN	683*	245*
CISPLATIN+DON-NO	142	120
ACYCLOVIR	-	208*
ACYCLOVIR+DON-NO	-	104

\*P< 0.05 with respect to the control values.

20

TABLE 2

STUDY OF THE RENAL FUNCTIONALITY IN ARTHRITIC RATS AFTER THE REPEATED TREATMENT WITH CYCLOSPORIN IN THE PRESENCE OR NOT OF A DON-NO. THE DATA ARE EXPRESSED AS PERCENT VARIATION WITH RESPECT TO THE CONTROL VALUE (GROUP TREATED WITH ONLY THE VEHICLE)		
TREATMENT	NAG	BLOOD CREATININE
VEHICLE	100	100
CYCLOSPORIN	220*	187*
CYCLOSPORIN+DON-NO	85	110

\*P<0.005 with respect to the control values

35

TABLE 3

STUDY OF THE RENAL FUNCTIONALITY IN ARTHRITIC RATS AFTER THE REPEATED TREATMENT WITH SOME ANTI-INFLAMMATORY COMPOUNDS, IN THE PRESENCE OR NOT OF DON-NO. THE DATA ARE EXPRESSED AS PERCENT VARIATION WITH RESPECT TO THE CONTROL VALUES (GROUP TREATED WITH ONLY THE VEHICLE)	
TREATMENT	BLOOD CREATININE
VEHICLE	100
IBUPROFEN	292*
IBUPROFEN+ SODIUM NITROPRUSSIATE (0.5 mg/kg s.c.)	123
IBUPROFEN+ NITROGLYCERIN (3 mg/kg s.c.)	142
INDOMETHACIN	355*
INDOMETHACIN+ SODIUM NITROPRUSSIATE (0.5 mg/kg s.c.)	138
INDOMETHACIN+ NITROGLYCERIN (3 mg/kg s.c.)	130
DICLOFENAC	371*
DICLOFENAC+ NITROGLYCERIN (3 mg/kg s.c.)	122

\*P< 0.05 with respect to the control values

TABLE 3 (continued)

5 STUDY OF THE RENAL FUNCTIONALITY IN ARTHRIC RATS AFTER THE REPEATED TREATMENT WITH  
 SOME ANTI-INFLAMMATORY COMPOUNDS, IN THE PRESENCE OR NOT OF DON-NO. THE DATA ARE  
 EXPRESSED AS PERCENT VARIATION WITH RESPECT TO THE CONTROL VALUES (GROUP TREATED WITH  
 ONLY THE VEHICLE)

TREATMENT	BLOOD CREATININE
NAPROXEN	323*
NAPROXEN+ NITROGLYCERIN (3 mg/kg s.c.)	164
ASPIRIN	280*
ASPIRIN+ NITROGLYCERIN (3 mg/kg s.c.)	112

10 \*P< 0.05 with respect to the control values

15

TABLE 4

20 STUDY OF THE RENAL FUNCTIONALITY IN HYPERTENSIVE RATS, AFTER THE REPEATED TREATMENT  
 WITH DICLOFENAC, IN THE PRESENCE OR NOT OF DON-NO. THE DATA ARE EXPRESSED AS PERCENT  
 VARIATION WITH RESPECT TO THE CONTROL VALUES (GROUP TREATED WITH ONLY THE VEHICLE)

TREATMENT	BLOOD CREATININE
VEHICLE	100
DICLOFENAC	287*
DICLOFENAC+ NITROGLYCERIN (3 mg/kg s.c.)	148

25 \*P< 0.05 with respect to the control values

30

TABLE 5

35 STUDY OF THE GASTROINTESTINAL TOLERABILITY IN RATS, AFTER THE REPEATED TREATMENT WITH  
 METHYLPREDNISOLONE, IN THE PRESENCE OR NOT OF A DON-NO. THE SEVERITY DEGREE OF THE  
 GASTROINTESTINAL PATHOLOGY WAS EVALUATED ACCORDING TO THE USUAL METHODS AND  
 EXPRESSED IN ARBITRARY VALUES. THE DATA ARE EXPRESSED AS PERCENT VARIATION WITH RESPECT  
 TO THE CONTROL VALUES (GROUP TREATED WITH ONLY THE VEHICLE)

TREATMENT	GASTROINTESTINAL HARM
VEHICLE	100
PREDNISOLONE	683*
PREDNISOLONE+SODIUM NITROPRUSSIATE (0.5 mg/kg s.c.)	142

40 \*P< 0.05 with respect to the control values

45

TABLE 6

50 STUDY OF THE RENAL FUNCTIONALITY IN ONCOLOGIC PATIENTS, AFTER THE TREATMENT WITH  
 CISPLATIN, IN THE PRESENCE OR NOT OF A DON-NO. THE DATA ARE EXPRESSED AS PERCENT  
 VARIATION WITH RESPECT TO THE INITIAL VALUES.

TREATMENT	BLOOD CREATININE VALUES	
	INITIAL	FINAL
CISPLATIN	100	183*

55 \*P< 0.05 with respect to the control values.

TABLE 6 (continued)

STUDY OF THE RENAL FUNCTIONALITY IN ONCOLOGIC PATIENTS, AFTER THE TREATMENT WITH CISPLATIN, IN THE PRESENCE OR NOT OF A DON-NO. THE DATA ARE EXPRESSED AS PERCENT VARIATION WITH RESPECT TO THE INITIAL VALUES.		
TREATMENT	BLOOD CREATININE VALUES	
CISPLATIN+ NITROGLYCERIN PATCH	100	109

TABLE 7


EFFECTS ON NITROXYBUTYLNAPROXEN (NO-NAPROXEN) ON CAPSAICIN INDUCED BRONCHOCONSTRICTION IN ENALAPRIL-TREATED GUINEA PIGS	
TREATMENT	BRONCHOCONSTRICTION (%)
VEHICLE	100
ENALAPRIL	290
ENALAPRIL + NO-NAPROXEN	20

## Claims


25 1. Use of organic compounds containing the  $-ONO_2$  function, or inorganic compounds containing the  $-NO$  group or compositions comprising said compounds for the manufacture of a medicament to reduce the toxicity caused by drugs not containing nitroderivative groups to the gastrointestinal and/or renal and/or respiratory apparatus, said compounds being characterized in that they are nitric oxide NO donors, that is when they are put into contact in vitro with cells of the basal endothelium or platelets, and after incubation of 5 minutes at the temperature of 37°C are capable of releasing NO and activating the cGMP (Guanosine cyclic 3',5'-(hydrogen phosphate)) synthesis.

30 2. Use according to claim 1, wherein the organic compounds containing the  $-ONO_2$  function are selected among:

35 clonitrate (3-chloro-1,2-propanediol dinitrate) having the formula  $C_3H_5ClN_2O_6$  and formula of structure




40 erythrityltetranitrate (1,2,3,4 butanetetroltetranitrate) having the formula  $C_4H_6N_4O_{12}$  and formula of structure



45 50 55 mannitol hexanitrate having the formula  $C_6H_6N_6O_{18}$  and formula of structure


5



10

nicorandil (N-[2-(nitrooxy)ethyl]-3-pyridine-carboxamide) having the formula  $\text{C}_8\text{H}_9\text{N}_3\text{O}_4$  and formula of structure


20



25

nitroglycerin (1,2,3 propanetriol trinitrate) having the formula  $\text{C}_3\text{H}_5\text{N}_3\text{O}_9$  and formula of structure


30



35

pentaerythritoltetranitrate (2,2-bis [(nitrooxy)-methyl]-1,3-propanedioldinitrate) having the formula  $\text{C}_5\text{H}_8\text{N}_4\text{O}_{12}$  and formula of structure


40



45

pentinitrol (2,2-bis[(nitrooxy)methyl]-1,3-propanediolmononitrate) having the formula  $\text{C}_5\text{H}_9\text{N}_3\text{O}_{10}$  and formula of structure


50




55

propatylnitrate (2-ethyl-2-[(nitrooxy)methyl]-1,3-propanedioldinitrate) having the formula  $\text{C}_6\text{H}_{11}\text{N}_3\text{O}_9$  and for-

mula of structure



10 trolnitratephosphate (2,2',2"-nitrylrisethanoltrinitrate phosphate) (salt 1:2) having the formula  $\text{C}_6\text{H}_{18}\text{N}_4\text{O}_{17}\text{P}_2$  and formula of structure



20 3. Use according to claim 1 wherein the inorganic compounds containing the -NO group are selected from nitroprussiates.

25 4. Use according to claim 1, wherein the inorganic compounds containing the -NO group are sodium nitroprussiate (pentakis(cyano-C)nitrosylferrate(2-)disodium) having formula  $\text{Na}_2[\text{Fe}(\text{CN})_5\text{NO}]$ .

5. Use according to claim 1 wherein the drugs not containing nitroderivative groups, causing renal and/or gastrointestinal and/or respiratory toxicity belong to the following therapeutic classes:

30 anti-tumoral, immunodepressive, anti-viral drugs, non-steroidal anti-inflammatory drugs, anti-thrombotic drugs, steroid anti-inflammatory drugs, antibiotics, inhibitors of the angiotensin-converting enzyme.

6. Use according to claim 1 wherein the drugs are chosen from:

35 anti-tumoral drugs chosen between cisplatin, 5 fluoro-uracil;  
 immunodepressive drugs chosen from cyclosporin;  
 anti-viral drugs chosen from acyclovir;  
 non-steroidal anti-inflammatory drugs chosen among ibuprofen, indomethacin, diclofenac, ketorolac, naproxen, ketoprofen, mefenamic acid, flunixin, flufenamic acid, niflumic acid;  
 40 anti-thrombotic drugs chosen from aspirin;  
 steroid anti-inflammatory drugs chosen among cortisone, dexamethasone, methylprednisolone;  
 antibiotics chosen between ciprofloxacin, gentamicine;  
 inhibitors of the angiotensin-converting enzyme chosen between captopril, enalapril;  
 45 beta-adrenergic antagonists, chosen among atenolol, metoprolol, timolol, propanol.

7. Use according to claim 1, wherein the drugs are chosen from:

the antitumoral is cisplatin, the immunodepressive is cyclosporin, the steroid anti-inflammatory drugs are dexamethasone, methylprednisolone.

50 8. Use according to claim 1, wherein the administration of the NO donor compounds is carried out by oral, parenteral or transdermic way.

9. Use according to claim 1 wherein the administration of NO donor compounds is carried out simultaneously, successively or previously to the drug causing the gastrointestinal and/or renal and/or respiratory toxicity.

55 10. Use according to claim 1 wherein the administration of NO donor compounds is carried out by transdermic way under the form of patches or plasters.

11. Use according to claim 1 wherein the patches are based on nitroglycerine.

12. Use according to claim 1, wherein the dosages are those used for the nitroderivative compounds for cardiovascular applications in human therapy.


5

**Patentansprüche**


10 1. Verwendung von organischen Verbindungen mit der funktionellen  $\text{-ONO}_2$ -Gruppe, von anorganischen Verbindungen mit der  $\text{-NO}$ -Gruppe oder von Zusammensetzungen, welche die besagten Verbindungen enthalten, zur Herstellung eines Medikaments zur Verringerung der Toxizität von Arzneimitteln, die keine Nitroderivatgruppen enthalten, für den gastrointestinalen und/oder renalen und/oder Atmungsbereich,  
 15 **dadurch gekennzeichnet, daß** sie Stickstoffmonoxid-NOdonoren sind, das heißt bei in-vitro-Kontakt mit Zellen des vasalen Endothels oder Blutplättchens nach Inkubation von 5 Minuten bei einer Temperatur von  $37^\circ\text{C}$  NO freisetzen und die Synthese von cGMP (cyclisches 3',5'-Guanosinhydrogenphosphat) aktivieren können.

20 2. Verwendung nach Anspruch 1, **dadurch gekennzeichnet, daß** die organischen Verbindungen mit der  $\text{-ONO}_2$ -Funktion ausgewählt sind aus:


25 Clonitrat (3-Chlor-1,2-propandiol-dinitrat) mit der Formel  $\text{C}_3\text{H}_5\text{ClN}_2\text{O}_6$  und der Strukturformel



30 Erythritytetranitrat (1,2,3,4-Butantetroltetranitrat) mit der Formel  $\text{C}_4\text{H}_6\text{N}_4\text{O}_{12}$  und der Strukturformel




35 40 Mannitolhexanitrat mit der Formel  $\text{C}_6\text{H}_8\text{N}_6\text{O}_{18}$  und der Strukturformel



45 50 55 Nicorandil (N-[2-(nitrooxy)ethyl]-3-pyridincarboxamid) mit der Formel  $\text{C}_8\text{H}_9\text{N}_3\text{O}_4$  und der Strukturformel


5



10

Nitroglycerin (1,2,3-Propanetrioltrinitrat) mit der Formel C<sub>3</sub>H<sub>5</sub>N<sub>3</sub>O<sub>9</sub> und der Strukturformel


15



20

Pentaerythritoltetranitrat (2,2-bis[(Nitrooxy)methyl]-1,3-propandioldinitrat) mit der Formel C<sub>5</sub>H<sub>8</sub>N<sub>4</sub>O<sub>12</sub> und der Strukturformel


25



30

Pentinitrol (2,2-bis[(Nitrooxy)methyl]-1,3-propandiolmononitrat) mit der Formel C<sub>5</sub>H<sub>9</sub>N<sub>3</sub>O<sub>10</sub> und der Strukturformel


35



40

Propatylnitrat (2-Ethyl-2-[(Nitrooxy)methyl]-1,3-propandioldinitrat) mit der Formel C<sub>6</sub>H<sub>11</sub>N<sub>3</sub>O<sub>9</sub> und der Strukturformel


45



50

Trolnitratphosphat (2,2',2"-Nitrylrisethanoltrinitratphosphat) (1:2-Salz) mit der Formel C<sub>6</sub>H<sub>18</sub>N<sub>4</sub>O<sub>17</sub>P<sub>2</sub> und der Strukturformel

55



10 3. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die anorganischen, die NO-Gruppe enthaltenden Verbindungen aus Nitroprussiaten ausgewählt sind.

15 4. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die anorganischen, die NO-Gruppe enthaltenden Verbindungen Natriumnitroprussiate (2-Dinatrium-pentakis(cyano-C)nitrosylferrate der Formel  $\text{Na}_2[\text{Fe}(\text{CN})_5\text{NO}]$  sind.

20 5. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Arzneimittel, die keine Nitroderivatgruppen enthalten und renale und/oder gastrointestinale und/oder Atmungstoxizität verursachen, den folgenden therapeutischen Klassen angehören: Antitumorarzneimittel, immunsuppressive, antivirale Arzneimittel, nichtsteroide entzündungshemmende Arzneimittel, antithrombotische Arzneimittel, steroide entzündungshemmende Arzneimittel, Antibiotica, Hemmer des Angiotensin-umwandelnden Enzyms.

25 6. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Arzneimittel wie folgt ausgewählt sind:

25 Antitumorarzneimittel aus Cisplatin, 5-Fluoruracil; als immunsuppressive Arzneimittel Cyclosporin; als antivirale Arzneimittel Acyclovir; nichtsteroide entzündungshemmende Arzneimittel aus Ibuprofen, Indomethacin, Diclofenac, Ketorolac, Naproxen, Ketoprofen, Mefenaminsäure, Flunixin, Flufenaminsäure, Nifluminsäure; als antithrombotisches Arzneimittel Aspirin; steroide entzündungshemmende Arzneimittel aus Cortison, Dexamethason, Methylprednisolon; Antibiotica aus Ciprofloxacin, Gentamicin; Hemmer des Angiotensin-umwandelnden Enzyms aus Captopril, Enalapril;  $\beta$ -adrenerge Antagonisten aus Atenolol, Metoprolol, Timolol, Propanol.

30 7. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Arzneimittel wie folgt ausgewählt sind:

35 das Antitumormittel ist Cisplatin, das Immunsuppressivum ist Cyclosporin, steroide entzündungshemmende Arzneimittel sind Dexametason, Methylprednisolon.

40 8. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die NO-Donorverbindungen auf oralem, parenteralem oder transdermalem Wege verabreicht werden.

45 9. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Verabreichung der NO-Donorverbindungen gleichzeitig, nachträglich oder vorhergehend zum Arzneimittel erfolgt, das die gastrointestinale und/oder renale und/oder Atmungstoxizität verursacht.

50 10. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Verabreichung der NO-Donorverbindungen auf transdermalem Wege in Form von Tupfern oder Pflastern erfolgt.

55 11. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Tupfer eine Nitroglycerinbasis enthalten.

12. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Nitroderivatverbindungen in den Dosierungen verwendet wurden wie sie für die Therapie von Herzgefäßen beim Menschen eingesetzt werden.


55 **Revendications**

1. Utilisation de composés organiques contenant la fonction  $-\text{ONO}_2$  ou de composés inorganiques contenant le groupe  $-\text{NO}$  ou de compositions comprenant lesdits composés pour la fabrication d'un médicament destiné à réduire


la toxicité provoquée par les médicaments ne contenant pas de groupes dérivés nitrés sur l'appareil gastrointestinal et/ou rénal et/ou respiratoire, lesdits composés étant caractérisés en ce que ce sont des donneurs d'oxyde nitrique NO, c'est-à-dire que, quand ils sont mis en contact in vitro avec des cellules de l'endothélium vasculaire ou avec des plaquettes, et après incubation pendant 5 minutes à la température de 37°C, ils sont capables de libérer le NO et d'activer la synthèse du cGMP (guanosine-3',5'-(hydrogénophos-phate)cyclique).

5 2. Utilisation selon la revendication 1, dans laquelle les composés organiques contenant la fonction -ONO<sub>2</sub> sont choisis parmi :


10 le clonitrate (dinitrate de 3-chloro-1,2-propanediol), ayant la formule C<sub>3</sub>H<sub>5</sub>ClN<sub>2</sub>O<sub>6</sub> et la formule développée



20 le tétranitrate d'érythrityle (tétranitrate de 1,2,3,4-butanetétrol), ayant la formule C<sub>4</sub>H<sub>6</sub>N<sub>4</sub>O<sub>12</sub> et la formule développée




35 l'hexanitrate de mannitol, ayant la formule C<sub>6</sub>H<sub>8</sub>N<sub>6</sub>O<sub>18</sub> et la formule développée



40 45 50 55 le nicorandil (N-[2-(nitrooxy)éthyl]-3-pyridine-carboxamide) ayant la formule C<sub>8</sub>H<sub>9</sub>N<sub>3</sub>O<sub>1</sub> et la formule développée

pée


5



10

la nitroglycérine (trinitale de 1,2,3-propanetriol), ayant la formule  $C_3H_5N_3O_9$  et la formule développée


15



20

le tétranitrate de pentaérythritol (dinitrate de 2,2-bis[(nitrooxy)-méthyl]-1,3-propanediol), ayant la formule  $C_5H_8N_4O_{12}$  et la formule développée


25



35

le pentrinitrol (mononitrate de (2,2-bis[(nitrooxy)méthyl]-1,3-propanediol) ayant la formule  $C_5H_9N_3O_{10}$  et la formule développée

40




45

50

le nitrate de propatyl(dinitrate de 2-éthyl-2-[(nitrooxy)méthyl]-1,3-propanediol) ayant la formule  $C_6H_{11}N_3O_9$  et la formule développée


55



10

Le phosphate de trolnitrate (le trinitrate et phosphate de 2,2',2"-nitrylriséthanol (sel 1:2) ayant la formule  $\text{C}_6\text{H}_{18}\text{N}_4\text{O}_{17}\text{P}_2$  et la formule développée

15



20

3. Utilisation selon la revendication 1, dans laquelle les composés inorganiques contenant le groupe -NO sont choisis parmi les nitroprussiates.

25

4. Utilisation selon la revendication 1, dans laquelle les composés inorganiques contenant le groupe -NO sont le nitroprussiate de sodium (pentakis-cyano-C)nitrosylferrate(2-)disodique ayant la formule  $\text{Na}_2[\text{Fe}(\text{CN})_5\text{NO}]$ .

30

5. Utilisation selon la revendication 1, dans laquelle les médicaments ne contenant pas de groupes dérivés nitrés, provoquant une toxicité rénale et/ou gastro-intestinale et/ou respiratoire, appartiennent aux classes thérapeutiques suivantes : les anti-tumoraux, les immunodépresseurs, les médicaments antiviraux, les médicaments anti-inflammatoires non stéroïdiens, les médicaments anti-thrombotiques, les médicaments anti-inflammatoires stéroïdiens, les antibiotiques, les inhibiteurs de l'enzyme de conversion de l'angiotensine.

35

6. Utilisation selon la revendication 1, dans laquelle les médicaments sont choisis parmi :

les médicaments anti-tumoraux choisis parmi le cisplatine, le 5-fluorouracile ;

les médicaments immunodépresseurs choisis parmi la cyclosporine ;

les médicaments antiviraux choisis parmi l'acyclovir ;

les médicaments anti-inflammatoires non stéroïdiens choisis parmi l'ibuprofène, l'indométhacine, le diclofénac, le kétorolac, le naproxène, le kétoprofène, l'acide méfénamique, la flunixine, l'acide flufenamique, l'acide niflumique ;

les médicaments anti-thrombotiques choisis parmi l'aspirine ;

les médicaments anti-inflammatoires stéroïdiens choisis parmi la cortisone, la dexaméthasone, la méthylprednisolone ;

les antibiotiques choisis parmi la cyprofloxacine, la gentamicine ;

les inhibiteurs de l'enzyme de conversion de l'angiotensine choisis parmi le captopril, l'éNALAPRIL ;

les antagonistes bêta-adrénergiques choisis parmi l'aténolol, le métaproterol, le timolol, le propanol.

45

7. Utilisation selon la revendication 1, dans laquelle les médicaments sont choisis parmi :

l'antitumoral est le cisplatine, l'immunodépresseur est la cyclosporine, les médicaments anti-inflammatoires stéroïdiens sont la dexaméthasone, la méthylprednisolone.

50

8. Utilisation selon la revendication 1, dans laquelle l'administration des composés donneurs de NO est réalisée par voie orale, parentale ou transdermique.

55

9. Utilisation selon la revendication 1, dans laquelle l'administration de composés donneurs de NO est réalisée simultanément, postérieurement ou antérieurement au médicament provoquant la toxicité gastro-intestinale et/ou

rénale et/ou respiratoire.

10. Utilisation selon la revendication 1, dans laquelle l'administration de composés donneurs de NO est mise en oeuvre par voie transdermique sous forme de timbres ou de plâtres.

5

11. Utilisation selon la revendication 1, dans laquelle les timbres sont à base de nitroglycérine.

12. Utilisation selon la revendication 1, dans laquelle les posologies sont celles qui sont utilisées pour les composés dérivés nitrés pour applications cardiovasculaires en thérapie humaine.

10

15

20

25

30

35

40

45

50

55